Viewing nowTerbinafine Tablets (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.

MFDS item code 201500625 · Approved 2015.02.05 · Insurance code 658202710
Treatment of onychomycosis, dermatomycosis (such as tinea pedis and tinea corporis), and tinea capitis
In adults, it is used for tinea pedis, tinea corporis, tinea cruris, and onychomycosis due to dermatophytes. In children, it is used for the treatment of tinea capitis.
Administer terbinafine at a dose of 125 mg twice daily or 250 mg once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris (jock itch): 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. A treatment duration of 3 months is usually sufficient for toenail infections, but in some patients it may take 6 months or longer. The treatment duration may be longer in patients with slow nail growth. For patients with a creatinine clearance of less than 50 mL/min, reduce the daily dose by 1/2.
Administer to children 2 years of age and older. Administration is not recommended for children under 2 years of age because there is no experience with its use in this age group. Tinea capitis: 4 weeks To prevent recurrence of the infection, treatment should be given regularly for the appropriate prescribed duration. Body weight under 20 kg (under 5 years of age): Administer 62.5 mg once daily. Because experience with its use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years of age): Administer 125 mg once daily. Body weight over 40 kg (over 12 years of age): Administer 250 mg once daily.
This medication is not recommended for patients with chronic liver disease or active liver disease. Before administration, it is essential to check for a history of liver disease and to conduct liver function tests, which should be repeated regularly during treatment. If symptoms of liver dysfunction occur, discontinue the medication immediately and consult a physician. It should not be administered to patients with blood disorders, severe renal impairment, infants under 2 years of age, or nursing mothers. Patients with hypersensitivity to this drug should also avoid taking it. Use with caution in patients with impaired renal function or elderly patients, and those under 20 kg; consult a physician immediately if any adverse reactions occur. If severe rashes or allergic reactions develop on the skin, administration should be stopped immediately. This drug may cause various side effects, including hepatotoxicity, hematological abnormalities, skin reactions, myalgia, and gastrointestinal symptoms, so report any unusual symptoms to a healthcare professional. This drug may interact with specific medications; therefore, inform your doctor or pharmacist if you are taking other medications. Pregnant women or those who may become pregnant should carefully consider the risks and benefits before taking this medication. If nursing, breastfeeding should be discontinued during the use of this drug. Store this medication out of reach of children, avoiding direct sunlight, and at room temperature. In case of overdose, symptoms such as headache, nausea, and dizziness may occur, and appropriate medical treatment should be sought immediately.
Liver failure, hepatitis, cholestasis, jaundice, rash, pruritus, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, vesicular dermatitis, psoriatic rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, elevated myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, upper abdominal discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, taste loss, taste disturbance, dizziness, drowsiness, paresthesia, sensory deficits, reduced attention, insomnia, elevated BUN, frequency of urination, vision impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, increased serum total cholesterol, elevated triglyceride levels, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, visual impairment, hearing loss, auditory dysfunction, vasculitis, permanent anosmia, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine kinase, headache, nausea, upper abdominal pain, dizziness
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It should be kept at room temperature between 1°C and 30°C, away from extreme heat or cold.
White round tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.